third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)

DRUG2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)Non-small Cell Lung CancerThird-generation TKI

Phase 2

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Not yet recruitingNCT06452433

Cancer Institute and Hospital, Chinese Academy of Medical SciencesNon-small Cell Lung Cancer

Start: 2024-06-01End: 2028-02-02Target: 91Updated: 2024-06-11

Unknown Phase

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

CompletedNCT06613633

Fudan UniversityNSCLC (Advanced Non-small Cell Lung Cancer), Third-generation TKI

Start: 2018-09-01End: 2026-02-20Updated: 2026-04-29